AI and machine learning

Streamlining and automating applications of BCP

As an image based technology, BCP can leverage advances in computer vision to bring it to the next level. Since 2018, Linnaeus Bioscience has been using artificial intelligence and machine learning approaches to streamline and automate mechanism of action (MOA) determination.

We initially developed AI applications for E. coli and with support from the Bill and Melinda Gates Foundation, Linnaeus was able to develop and deploy a truly comprehensive AI platform capable of correctly identifying the MOA for virtually all classes of antibiotics effective against M. tuberculosis.

Linnaeus Bioscience is in the process of developing similar systems for other bacteria and additional mycobacterial pathogens.

Antifungal assays

Linnaeus Bioscience has leveraged its experience with bacterial systems to develop its Fungal Cytological Profiling (FCP) platform to help accelerate the discovery and development of novel antifungals, a badly needed class of anti-infectives. Linnaeus Bioscience has met that need and developed platforms for Candida albicans  and Cryptococcus neoformans. These platforms allow Linnaeus Bioscience to intervene early in the antifungal drug discovery pipeline to rapidly characterize MOA of candidate molecules, identify and prioritize leads and quickly provide rich SAR data.

Bacteriophage assays

Leverage our experience studying and working with phage

Our team at Linnaeus Bioscience has expertise in studying and characterizing phage used for phage therapy. We offer a variety of services aimed at phage and together with our common assays can be a single vendor for all your needs.

  • Potency on solid or liquid media
  • High throughput phage-bacteria susceptibility testing and time-to-lysis assays
  • Phage mechanisms of action
  • Resistance mechanisms frequency of resistance and potential receptor identification
  • Phage-antibiotic synergy
  • Phage discovery

Hepatitis B capsid inhibitors

Capsid assembly assay or inhibitors and to identify resistance

Hepatitis B capsid assembly is an important target of many compounds in clinical development. Linnaeus Bioscience has developed and validated a cell-based assay for studying compounds that alter or prevent proper capsid assembly.

  • Rapid assay can be used to quickly screen thousands of analogs for relative potency and classify MOA
  • Directly examine reversibility
  • Understand the potential for resistance by screening a large library of capsid variants
  • Screen patients prior to enrolling in clinical trials and to monitor patients for resistance while on therapy